2023
DOI: 10.12688/wellcomeopenres.19795.1
|View full text |Cite
|
Sign up to set email alerts
|

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya

Samuel Sang,
Mehreen S. Datoo,
Edward Otieno
et al.

Abstract: Background: Falciparum malaria remains a global health problem. Two vaccines, based on the circumsporozoite antigen, are available.  RTS, S/AS01 was recommended for use in 2021 following the advice of the World Health Organisation (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization and WHO Malaria Policy Advisory Group (MPAG). It has since been pre-qualified in 2022 by the WHO. R21 is similar to RTS, S/AS01, and recently licensed in Nigeria, Ghana and Burkina Faso following Phase 3 trial results. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
references
References 10 publications
0
0
0
Order By: Relevance